Intracellular glycosylation and development

Biochimica et Biophysica Acta - General Subjects

Volumn 1573, Issue 3, 2002, Pages 336-345

  O'Donnell, Niall ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

O GlcNAc; O GlcNAc transferase; Protein degradation; Transcription factor; UDP GlcNAc metabolism

Indexed keywords

CELL PROTEIN; CYTOPLASM PROTEIN; DNA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; MYC PROTEIN; N ACETYLGLUCOSAMINE; NUCLEAR FACTOR I; NUCLEAR PROTEIN; PHOSPHOPROTEIN; RNA POLYMERASE II; SERINE; SYNAPSIN I; THREONINE; TRANSCRIPTION FACTOR SP1;

AMINO ACID SUBSTITUTION; CELL FUNCTION; DEVELOPMENT; GLYCOSYLATION; NONHUMAN; ORGAN DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW;

ANIMALS; EMBRYONIC AND FETAL DEVELOPMENT; GLYCOSYLATION; HUMANS; INTRACELLULAR FLUID; MICE; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROTEINS; URIDINE DIPHOSPHATE N-ACETYLGLUCOSAMINE;

EID: 0037137472     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(02)00401-4     Document Type: Review

References (125)

1. Comer F.I., Hart G.W. O-GlcNAc and the control of gene expression. Biochim. Biophys. Acta. 1473:1999;161-171.
2. Comer F.I., Hart G.W. O-Glycosylation of nuclear and cytosolic proteins. Dynamic interplay between O-GlcNAc and O-phosphate. J. Biol. Chem. 275:2000;29179-29182.
3. Hart G.W., Greis K.D., Dong L.Y., Blomberg M.A., Chou T.Y., Jiang M.S., Roquemore E.P., Snow D.M., Kreppel L.K., Cole R.N.et al. O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Adv. Exp. Med. Biol. 376:1995;115-123.
4. Kearse K.P., Hart G.W. Lymphocyte activation induces rapid changes in nuclear and cytoplasmic glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 88:1991;1701-1705.
5. Kreppel L.K., Blomberg M.A., Hart G.W. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem. 272:1997;9308-9315.
6. Kreppel L.K., Hart G.W. Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J. Biol. Chem. 274:1999;32015-32022.
7. Lubas W.A., Frank D.W., Krause M., Hanover J.A. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem. 272:1997;9316-9324.
8. Lubas W.A., Hanover J.A. Functional expression of O-linked GlcNAc transferase. Domain structure and substrate specificity. J. Biol. Chem. 275:2000;10983-10988.
9. Gao Y., Wells L., Comer F.I., Parker G.J., Hart G.W. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J. Biol. Chem. 276:2001;9838-9845.
10. Zhivkov V., Tosheva R., Zhivkova Y. Concentration of uridine diphosphate sugars in various tissues of vertebrates. Comp. Biochem. Physiol. 51B:1975;421-424.
11. Veerababu G., Tang J., Hoffman R.T., Daniels M.C., Hebert L.F. Jr., Crook E.D., Cooksey R.C., McClain D.A. Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes. 49:2000;2070-2078.
12. Simmons S.T., Daniels M.C., Huddleston E., Hebert L.F. Jr., McClain D.A., Crook E.D. Insulin stimulation of glutamine: fructose-6-phosphate amidotransferase occurs via an insulin-like growth factor-1 pathway in rat fibroblasts. Res. Commun. Mol. Pathol. Pharmacol. 104:1999;63-72.
13. Hebert L.F. Jr., Daniels M.C., Zhou J., Crook E.D., Turner R.L., Simmons S.T., Neidigh J.L., Zhu J.S., Baron A.D., McClain D.A. Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J. Clin. Invest. 98:1996;930-936.
14. Nelson B.A., Robinson K.A., Buse M.G. High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes. Diabetes. 49:2000;981-991.
15. Robinson L.J., Razzack Z.F., Lawrence J.C. Jr., James D.E. Mitogen-activated protein kinase activation is not sufficient for stimulation of glucose transport or glycogen synthase in 3T3-L1 adipocytes. J. Biol. Chem. 268:1993;26422-26427.
16. Robinson K.A., Sens D.A., Buse M.G. Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor. Diabetes. 42:1993;1333-1346.
17. Robinson K.A., Weinstein M.L., Lindenmayer G.E., Buse M.G. Effects of diabetes and hyperglycemia on the hexosamine synthesis pathway in rat muscle and liver. Diabetes. 44:1995;1438-1446.
18. Wang J., Liu R., Hawkins M., Barzilai N., Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature. 393:1998;684-688.
19. Rossetti L. Perspective: hexosamines and nutrient sensing. Endocrinology. 141:2000;1922-1925.
20. Liu K., Paterson A.J., Chin E., Kudlow J.E. Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2820-2825.
21. Boehmelt G., Wakeham A., Elia A., Sasaki T., Plyte S., Potter J., Yang Y., Tsang E., Ruland J., Iscove N.N., Dennis J.W., Mak T.W. Decreased UDP-GlcNAc levels abrogate proliferation control in EMeg32-deficient cells. EMBO J. 19:2000;5092-5104.
22. Boehmelt G., Fialka I., Brothers G., McGinley M.D., Patterson S.D., Mo R., Hui C.C., Chung S., Huber L.A., Mak T.W., Iscove N.N. Cloning and characterization of the murine glucosamine-6-phosphate acetyltransferase EMeg32. Differential expression and intracellular membrane association. J. Biol. Chem. 275:2000;12821-12832.
23. Shafi R., Iyer S.P., Ellies L.G., O'Donnell N., Marek K.W., Chui D., Hart G.W., Marth J.D. The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5735-5739.
24. Neufeld E.J., Pastan I. A mutant fibroblast cell line defective in glycoprotein synthesis due to a deficiency of glucosamine phosphate acetyltransferase. Arch. Biochem. Biophys. 188:1978;323-327.
25. Pouyssegur J.M., Pastan I. Mutants of Balb/c 3T3 fibroblasts defective in adhesiveness to substratum: evidence for alteration in cell surface proteins. Proc. Natl. Acad. Sci. U. S. A. 73:1976;544-548.
26. Pouyssegur J., Willingham M., Pastan I. Role of cell surface carbohydrates and proteins in cell behavior: studies on the biochemical reversion of an N-acetylglucosamine-deficient fibroblast mutant. Proc. Natl. Acad. Sci. U. S. A. 74:1977;243-247.
27. Patti M.E., Virkamaki A., Landaker E.J., Kahn C.R., Yki-Jarvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes. 48:1999;1562-1571.
28. Bruning J.C., Winnay J., Cheatham B., Kahn C.R. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol. Cell Biol. 17:1997;1513-1521.
29. Kim Y.B., Zhu J.S., Zierath J.R., Shen H.Q., Baron A.D., Kahn B.B. Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle. Diabetes. 48:1999;310-320.
30. Cristofanelli B., Valentinis B., Soddu S., Rizzo M.G., Marchetti A., Bossi G., Morena A.R., Dews M., Baserga R., Sacchi A. Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. Oncogene. 19:2000;3245-3255.
31. Saffer J.D., Jackson S.P., Annarella M.B. Developmental expression of Sp1 in the mouse. Mol. Cell Biol. 11:1991;2189-2199.
32. Armstrong S.A., Barry D.A., Leggett R.W., Mueller C.R. Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. J. Biol. Chem. 272:1997;13489-13495.
33. Black A.R., Jensen D., Lin S.Y., Azizkhan J.C. Growth/cell cycle regulation of Sp1 phosphorylation. J. Biol. Chem. 274:1999;1207-1215.
34. Borja P.F., Collins N.K., Du P., Azizkhan-Clifford J., Mudryj M. Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J. 20:2001;5737-5747.
35. Jackson S.P., Tjian R. O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell. 55:1988;125-133.
36. Jackson S.P., MacDonald J.J., Lees-Miller S., Tjian R. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell. 63:1990;155-165.
37. Jackson S., Gottlieb T., Hartley K. Phosphorylation of transcription factor Sp1 by the DNA-dependent protein kinase. Adv. Second Messenger Phosphoprot. Res. 28:1993;279-286.
38. Haltiwanger R.S., Grove K., Philipsberg G.A. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. J. Biol. Chem. 273:1998;3611-3617.
39. Han I., Kudlow J.E. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol. Cell Biol. 17:1997;2550-2558.
40. Roos M.D., Su K., Baker J.R., Kudlow J.E. O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol. Cell Biol. 17:1997;6472-6480.
41. Su K., Roos M.D., Yang X., Han I., Paterson A.J., Kudlow J.E. An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. J. Biol. Chem. 274:1999;15194-15202.
42. Su K., Yang X., Roos M.D., Paterson A.J., Kudlow J.E. Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp1. Biochem. J. 348(Pt. 2):2000;281-289.
43. Mortensen E.R., Marks P.A., Shiotani A., Merchant J.L. Epidermal growth factor and okadaic acid stimulate Sp1 proteolysis. J. Biol. Chem. 272:1997;16540-16547.
44. Yang X., Su K., Roos M.D., Chang Q., Paterson A.J., Kudlow J.E. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6611-6616.
45. Marin M., Karis A., Visser P., Grosveld F., Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell. 89:1997;619-628.
46. Henriksson M., Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68:1996;109-182.
47. Bouchard C., Staller P., Eilers M. Control of cell proliferation by Myc. Trends Cell Biol. 8:1998;202-206.
48. Eisenman R.N. Deconstructing myc. Genes Dev. 15:2001;2023-2030.
49. Grandori C., Eisenman R.N. Myc target genes. Trends Biochem. Sci. 22:1997;177-181.
50. Davis A.C., Wims M., Spotts G.D., Hann S.R., Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 7:1993;671-682.
51. Bazarov A.V., Adachi S., Li S.F., Mateyak M.K., Wei S., Sedivy J.M. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res. 61:2001;1178-1186.
52. Bush A., Mateyak M., Dugan K., Obaya A., Adachi S., Sedivy J., Cole M. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev. 12:1998;3797-3802.
53. Mateyak M.K., Obaya A.J., Adachi S., Sedivy J.M. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8:1997;1039-1048.
54. Eilers M., Schirm S., Bishop J.M. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J. 10:1991;133-141.
55. Bhatia K., Spangler G., Hamdy N., Neri A., Brubaker G., Levin A., Magrath I. Mutations in the coding region of c-myc occur independently of mutations in the regulatory regions and are predominantly associated with myc/Ig translocation. Curr. Top Microbiol. Immunol. 194:1995;389-398.
56. Bhatia K., Spangler G., Gaidano G., Hamdy N., Dalla-Favera R., Magrath I. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood. 84:1994;883-888.
57. Bhatia K., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet. 5:1993;56-61.
58. Chou T.Y., Hart G.W., Dang C.V. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J. Biol. Chem. 270:1995;18961-18965.
59. Chou T.Y., Dang C.V., Hart G.W. Glycosylation of the c-Myc transactivation domain. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4417-4421.
60. Bahram F., von der Lehr N., Cetinkaya C., Larsson L.G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 95:2000;2104-2110.
61. Chang D.W., Claassen G.F., Hann S.R., Cole M.D. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol. Cell Biol. 20:2000;4309-4319.
62. Gregory M.A., Hann S.R. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol. Cell Biol. 20:2000;2423-2435.
63. Muramatsu M., Inoue S. Estrogen receptors: how do they control reproductive and nonreproductive functions? Biochem. Biophys. Res. Commun. 270:2000;1-10.
64. Arts J., Kuiper G.G., Janssen J.M., Gustafsson J.A., Lowik C.W., Pols H.A., van Leeuwen J.P. Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology. 138:1997;5067-5070.
65. Couse J.F., Lindzey J., Grandien K., Gustafsson J.A., Korach K.S. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology. 138:1997;4613-4621.
66. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:1997;863-870.
67. Cheng X., Cole R.N., Zaia J., Hart G.W. Alternative O-glycosylation/O-phosphorylation of the murine estrogen receptor beta. Biochemistry. 39:2000;11609-11620.
68. Jiang M.S., Hart G.W. A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J. Biol. Chem. 272:1997;2421-2428.
69. Cheng X., Hart G.W. Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta: post-translational regulation of turnover and transactivation activity. J. Biol. Chem. 276:2001;10570-10575.
70. Couse J.F., Hewitt S.C., Bunch D.O., Sar M., Walker V.R., Davis B.J., Korach K.S. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science. 286:1999;2328-2331.
71. Couse J.F., Curtis Hewitt S., Korach K.S. Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J. Steroid Biochem. Mol. Biol. 74:2000;287-296.
72. Karas R.H., Hodgin J.B., Kwoun M., Krege J.H., Aronovitz M., Mackey W., Gustafsson J.A., Korach K.S., Smithies O., Mendelsohn M.E. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;15133-15136.
73. Krege J.H., Hodgin J.B., Couse J.F., Enmark E., Warner M., Mahler J.F., Sar M., Korach K.S., Gustafsson J.A., Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15677-15682.
74. Frain M., Swart G., Monaci P., Nicosia A., Stampfli S., Frank R., Cortese R. The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell. 59:1989;145-157.
75. Chouard T., Blumenfeld M., Bach I., Vandekerckhove J., Cereghini S., Yaniv M. A distal dimerization domain is essential for DNA-binding by the atypical HNF1 homeodomain. Nucleic Acids Res. 18:1990;5853-5863.
76. Lichtsteiner S., Schibler U. A glycosylated liver-specific transcription factor stimulates transcription of the albumin gene. Cell. 57:1989;1179-1187.
77. Lee Y.H., Sauer B., Gonzalez F.J. Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse. Mol. Cell Biol. 18:1998;3059-3068.
78. Pontoglio M., Barra J., Hadchouel M., Doyen A., Kress C., Bach J.P., Babinet C., Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell. 84:1996;575-585.
79. Pontoglio M., Sreenan S., Roe M., Pugh W., Ostrega D., Doyen A., Pick A.J., Baldwin A., Velho G., Froguel P., Levisetti M., Bonner-Weir S., Bell G.I., Yaniv M., Polonsky K.S. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J. Clin. Invest. 101:1998;2215-2222.
80. Shih D.Q., Navas M.A., Kuwajima S., Duncan S.A., Stoffel M. Impaired glucose homeostasis and neonatal mortality in hepatocyte nuclear factor 3alpha-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10152-10157.
81. Barrera-Hernandez G., Wanke I.E., Wong N.C. Effects of diabetes mellitus on hepatocyte nuclear factor 1 decrease albumin gene transcription. J. Biol. Chem. 271:1996;9969-9975.
82. Dahmus M.E. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J. Biol. Chem. 271:1996;19009-19012.
83. Dahmus M.E. Phosphorylation of mammalian RNA polymerase II. Methods Enzymol. 273:1996;185-193.
84. Kelly W.G., Dahmus M.E., Hart G.W. RNA polymerase II is a glycoprotein. Modification of the COOH-terminal domain by O-GlcNAc. J. Biol. Chem. 268:1993;10416-10424.
85. Bregman D.B., Du L., van der Zee S., Warren S.L. Transcription-dependent redistribution of the large subunit of RNA polymerase II to discrete nuclear domains. J. Cell Biol. 129:1995;287-298.
86. Du L., Warren S.L. A functional interaction between the carboxy-terminal domain of RNA polymerase II and pre-mRNA splicing. J. Cell Biol. 136:1997;5-18.
87. Greenleaf A.L. A positive addition to a negative tail's tale. Proc. Natl. Acad. Sci. U. S. A. 90:1993;10896-10897.
88. Kim E., Du L., Bregman D.B., Warren S.L. Splicing factors associate with hyperphosphorylated RNA polymerase II in the absence of pre-mRNA. J. Cell Biol. 136:1997;19-28.
89. Naar A.M., Lemon B.D., Tjian R. Transcriptional coactivator complexes. Annu. Rev. Biochem. 70:2001;475-501.
90. Comer F.I., Hart G.W. Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry. 40:2001;7845-7852.
91. Mitsui A., Sharp P.A. Ubiquitination of RNA polymerase II large subunit signaled by phosphorylation of carboxyl-terminal domain. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6054-6059.
92. Dong D.L., Xu Z.S., Chevrier M.R., Cotter R.J., Clevel D.W., Hart G.W. Glycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and M. J. Biol. Chem. 268:1993;16679-16687.
93. Dong D.L., Xu Z.S., Hart G.W., Cleveland D.W. Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H. J. Biol. Chem. 271:1996;20845-20852.
94. Lee M.K., Cleveland D.W. Neuronal intermediate filaments. Annu. Rev. Neurosci. 19:1996;187-217.
95. Williamson T.L., Marszalek J.R., Vechio J.D., Bruijn L.I., Lee M.K., Xu Z., Brown R.H. Jr., Cleveland D.W. Neurofilaments, radial growth of axons, and mechanisms of motor neuron disease. Cold Spring Harbor Symp. Quant. Biol. 61:1996;709-723.
96. Zhang X., Bennett V. Identification of O-linked N-acetylglucosamine modification of ankyrinG isoforms targeted to nodes of Ranvier. J. Biol. Chem. 271:1996;31391-31398.
97. Julien J.P., Beaulieu J.M. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J. Neurol. Sci. 180:2000;7-14.
98. Julien J.P., Couillard-Despres S., Meier J. Transgenic mice in the study of ALS: the role of neurofilaments. Brain Pathol. 8:1998;759-769.
99. Elder G.A., Friedrich V.L. Jr., Kang C., Bosco P., Gourov A., Tu P.H., Zhang B., Lee V.M., Lazzarini R.A. Requirement of heavy neurofilament subunit in the development of axons with large calibers. J. Cell Biol. 143:1998;195-205.
100. Elder G.A., Friedrich V.L. Jr., Pereira D., Tu P.H., Zhang B., Lee V.M., Lazzarini R.A. Mice with disrupted midsized and heavy neurofilament genes lack axonal neurofilaments but have unaltered numbers of axonal microtubules. J. Neurosci. Res. 57:1999;23-32.
101. Kriz J., Meier J., Julien J.P., Padjen A.L. Altered ionic conductances in axons of transgenic mouse expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 163:2000;414-421.
102. Zhou D., Lambert S., Malen P.L., Carpenter S., Boland L.M., Bennett V. AnkyrinG is required for clustering of voltage-gated Na channels at axon initial segments and for normal action potential firing. J. Cell Biol. 143:1998;1295-1304.
103. Arnold C.S., Johnson G.V., Cole R.N., Dong D.L., Lee M., Hart G.W. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J. Biol. Chem. 271:1996;28741-28744.
104. Ding M., Vandre D.D. High molecular weight microtubule-associated proteins contain O-linked-N-acetylglucosamine. J. Biol. Chem. 271:1996;12555-12561.
105. Trojanowski J.Q., Lee V.M. Transgenic models of tauopathies and synucleinopathies. Brain Pathol. 9:1999;733-739.
106. Trojanowski J.Q., Lee V.M. "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann. N. Y. Acad. Sci. 924:2000;62-67.
107. Yanagisawa M., Planel E., Ishiguro K., Fujita S.C. Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. FEBS Lett. 461:1999;329-333.
108. Lefebvre T., Alonso C., Mahboub S., Dupire M.J., Zanetta J.P., Caillet-Boudin M.L., Michalski J.C. Effect of okadaic acid on O-linked N-acetylglucosamine levels in a neuroblastoma cell line. Biochim. Biophys. Acta. 1472:1999;71-81.
109. Dawson H.N., Ferreira A., Eyster M.V., Ghoshal N., Binder L.I., Vitek M.P. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114:2001;1179-1187.
110. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., Sato-Yoshitake R., Takei Y., Noda T., Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 369:1994;488-491.
111. Takei Y., Kondo S., Harada A., Inomata S., Noda T., Hirokawa N. Delayed development of nervous system in mice homozygous for disrupted microtubule-associated protein 1B (MAP1B) gene. J. Cell Biol. 137:1997;1615-1626.
112. Takei Y., Teng J., Harada A., Hirokawa N. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J. Cell Biol. 150:2000;989-1000.
113. Greengard P., Benfenati F., Valtorta F. Synapsin I, an actin-binding protein regulating synaptic vesicle traffic in the nerve terminal. Adv. Second Messenger Phosphoprot. Res. 29:1994;31-45.
114. Cole R.N., Hart G.W. Glycosylation sites flank phosphorylation sites on synapsin I: O-linked N-acetylglucosamine residues are localized within domains mediating synapsin I interactions. J. Neurochem. 73:1999;418-428.
115. Ryan T.A., Li L., Chin L.S., Greengard P., Smith S.J. Synaptic vesicle recycling in synapsin I knock-out mice. J. Cell Biol. 134:1996;1219-1227.
116. Ferreira A., Chin L.S., Li L., Lanier L.M., Kosik K.S., Greengard P. Distinct roles of synapsin I and synapsin II during neuronal development. Mol. Med. 4:1998;22-28.
117. Nemeth A.H., Nolte D., Dunne E., Niemann S., Kostrzewa M., Peters U., Fraser E., Bochukova E., Butler R., Brown J., Cox R.D., Levy E.R., Ropers H.H., Monaco A.P., Muller U. Refined linkage disequilibrium and physical mapping of the gene locus for X-linked dystonia-parkinsonism (DYT3). Genomics. 60:1999;320-329.
118. Waters C.H., Faust P.L., Powers J., Vinters H., Moskowitz C., Nygaard T., Hunt A.L., Fahn S. Neuropathology of lubag (x-linked dystonia parkinsonism). Mov. Disord. 8:1993;387-390.
119. Heard E., Clerc P., Avner P. X-chromosome inactivation in mammals. Annu. Rev. Genet. 31:1997;571-610.
120. Chapman V.M. Rossant J., Pedersen R.A. Experimental Approaches to Mammalian Embryonic Development. 1986;365-398 Cambridge Univ. Press, Cambridge.
121. Tam P.P., Williams E.A., Tan S.S. Expression of an X-linked HMG-lacZ transgene in mouse embryos: implication of chromosomal imprinting and lineage-specific X-chromosome activity. Dev. Genet. 15:1994;491-503.
122. Tan S.S., Faulkner-Jones B., Breen S.J., Walsh M., Bertram J.F., Reese B.E. Cell dispersion patterns in different cortical regions studied with an X-inactivated transgenic marker. Development. 121:1995;1029-1039.
123. Molinari E., Gilman M., Natesan S. Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo. EMBO J. 18:1999;6439-6447.
124. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr. Opin. Cell Biol. 9:1997;788-799.
125. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.